Many of Australia’s top brokers have been busy adjusting their financial models and recommendations again. This has led to a number of broker notes being released this week.
Three ASX shares that brokers have named as buys this week are listed below. Here’s why their analysts are feeling bullish on them right now:
Guzman Y Gomez Ltd (ASX: GYG)
According to a note out of Morgans, its analysts have retained their buy rating on this burrito seller’s shares with an improved price target of $26.70. This follows the release of a third-quarter update that impressed the broker. It highlights that Guzman Y Gomez delivered a meaningful acceleration in Australian comparable store sales growth, providing tangible evidence that the business is executing well against a challenging consumer backdrop. It also points out that transaction growth continued to outpace comparable store sales growth. This maintains its strategy to be volume and frequency-led rather than price-driven. The Guzman Y Gomez share price is fetching $19.50 at the time of writing.
Lovisa Holdings Ltd (ASX: LOV)
A note out of UBS reveals that its analysts have upgraded this fashion jewellery retailer’s shares to a buy rating with a $26.00 price target. UBS highlights that Lovisa’s shares have fallen heavily this year amid concerns over slower store growth, softer like-for-like sales in the local market, and ongoing losses from the new Jewells store brand. However, the broker believes much of this risk is now priced in. Furthermore, it thinks the resilience of Lovisa’s youth-focused, low price point offering is underappreciated by the market, and expects management to prevent sustained losses from Jewells either by fixing the business or considering a closure. The Lovisa share price is trading at $23.96 this afternoon.
Telix Pharmaceuticals Ltd (ASX: TLX)
A note out of Bell Potter reveals that its analysts have retained their buy rating and $19.00 price target on this radiopharmaceuticals company’s shares. This follows the release of a solid first-quarter sales update this week. Bell Potter was pleased with Telix’s update and believes it leaves the company well-placed to achieve its guidance in FY 2026. In addition, it highlights that Telix continues to make good progress on multiple pipeline products. It also sees major short term share price catalysts on the horizon. This includes the potential acceptance by the FDA of the resubmitted NDA for Pixclara and the amendment to the IND for TLX591. The Telix share price is fetching $13.83 at the time of writing.
The post Top brokers name 3 ASX shares to buy today appeared first on The Motley Fool Australia.
Should you invest $1,000 in Guzman Y Gomez right now?
Before you buy Guzman Y Gomez shares, consider this:
Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Guzman Y Gomez wasn’t one of them.
The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
And right now, Scott thinks there are 5 stocks that may be better buys…
* Returns as of 20 Feb 2026
.custom-cta-button p {
margin-bottom: 0 !important;
}
More reading
- GYG shares skyrocket 33% this week: Is this the recovery we’ve been waiting for?
- Morgans names two ASX 200 shares to buy and one to sell this week
- 5 things to watch on the ASX 200 on Wednesday
- Why rebounding Telix shares could still rise 40%
- Why Bell Potter just downgraded its valuation of this popular ASX 200 share
Motley Fool contributor James Mickleboro has positions in Lovisa. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Lovisa and Telix Pharmaceuticals. The Motley Fool Australia has recommended Lovisa and Telix Pharmaceuticals. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.